Sofinnova Partners Closed MD Start IV Fund
The firm successfully raised €82 million to fuel its medtech company-creation strategy.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you believe private venture capital investment effectively accelerates the development of helpful new medical technology?
Sofinnova Partners has officially closed its oversubscribed Sofinnova MD Start IV fund at €82 million. The firm manages over €4 billion in total assets and focuses on accelerating medtech innovation.
Why it matters
The new capital will enable the firm to expand its company-creation strategy across Europe and the US. It aims to support founders with both financial investment and operational expertise.
The MD Start IV fund reached €82 million, surpassing the €63 million raised for the previous iteration. Sofinnova Partners manages over €4 billion in assets and has backed 500 companies since its founding.
The players
Sofinnova Partners
This is a venture capital firm based in Paris, London, and Milan that focuses on the healthcare and life sciences sectors.
Anne Osdoit
She is a partner at Sofinnova Partners and plays a leadership role in the firm's medtech investment strategy.
Cecile Dupont
She serves as a partner at the firm, helping guide investment decisions and operational support for new company creation.
Mano Iyer
He is a partner at Sofinnova Partners and is responsible for leading the firm's strategic medtech initiatives.
The details
Led by partners Anne Osdoit, Cecile Dupont, and Mano Iyer, the fund provides capital along with hands-on operational support to startups. The firm plans to launch six to eight new medtech companies over the next five years.
Timeline
Sofinnova Partners was founded in 1972.
The firm announced the final close of the fund on September 28, 2026.
The launch of six to eight new medtech companies is planned over the next five years.
Market Landscape
The firm is scaling its operations as competition for high-growth medical technology assets intensifies across global markets. This move positions the company to maintain its momentum in the sector compared to other specialized life science venture firms.
This move does not directly change retail pricing or consumer healthcare access but signals a pipeline of future medical technology products. Investors and industry stakeholders should monitor the firm's upcoming launches for potential shifts in the medtech market.
The takeaway
The successful closure of this oversubscribed fund underscores ongoing investor confidence in specialized medtech company-creation models. Founders in the early-stage medical technology space may see increased opportunities for operational support through such dedicated venture platforms.
Further reading
Learn more about the latest developments in the Healthcare sector.
Live Poll
Do you believe private venture capital investment effectively accelerates the development of helpful new medical technology?
